Company
Headquarters: Taizhou, China
Employees: 3,586
CN¥16.53 Billion
CNY as of Jan. 1, 2026
US$2.36 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Zhejiang Jiuzhou Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients (API) and intermediates in China and internationally. Its API pipeline comprise central nervous system, non-steroidal, anti-infection, hypoglycemic and antiviral, tumor treatment, anti-depressant, Parkinson, HCV drugs, diabetes, cardiovascular, and respiratory anti-infection drugs. The company also provides asymmetric catalysts and lithium battery materials. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥5.36 B |
| EBITDA | CN¥1.06 B |
| Gross Profit TTM | CN¥1.77 B |
| Profit Margin | 13.50% |
| Operating Margin | 26.82% |
| Quarterly Revenue Growth | 7.40% |
Zhejiang Jiuzhou Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603456 wb_incandescent